The utility of the combined use of 123 I-FP-CIT SPECT and neuromelanin MRI in differentiating Parkinson's disease from other parkinsonian syndromes

Abstract

Background

Neuromelanin magnetic resonance imaging (NmMRI) and ¹²³I-FP-CIT dopamine transporter single photon emission computed tomography (DAT-SPECT) provide specific information that distinguishes Parkinson's disease (PD) from non-degenerative parkinsonian syndrome (NDPS).

Purpose

To determine whether a multiparametric scoring system (MSS) could improve accuracy compared to each parameter of DAT-SPECT and NmMRI in differentiating PD from NDPS.

Material and Methods

A total of 49 patients, including 14 with NDPS, 30 with PD, and five with atypical parkinsonian disorder (APD) underwent both NmMRI and DAT-SPECT and were evaluated. The average (Ave) and the asymmetry index (AI) were calculated in the substantia nigra compacta area (SNc-area), SNc midbrain-tegmentum contrast ratio (SNc-CR), and specific binding ratio (SBR). Cut-off values were determined, using receiver operating characteristic (ROC) analysis, for the differentiation of PD from NDPS on the statistically significant parameters. All cases were scored as either 1 (PD) or 0 (NDPS) for each parameter according to its threshold. These individual scores were totaled for each case, yielding a combined score for each case to obtain a cut-off value for the MSS.

Results

The Ave-SNc-area, Ave-SNc-CR, and Ave-SBR in PD were significantly lower than those in NDPS. The AI-SNc-area and AI-SBR in PD were significantly higher than those in NDPS. Of the five parameters, the highest accuracy was 93% for the Ave-SNc-area. For the MSS, a cut-off value of 3 was the accuracy of 96%. Besides, no significant difference was observed between PD and APD on all parameters.

Conclusion

An MSS has comparable or better accuracy compared to each parameter of DAT-SPECT and NmMRI in distinguishing PD from NDPS.

Keywords

Magnetic resonance imaging neuromelanin imaging dopamine transporter imaging Parkinson's disease combined analysis

Get full access to this article

View all access options for this article.

References

Nikolaus

Antke

Kley

, et al. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev Neurosci 2007; 18: 439–472.

Nikolaus

Antke

Müller

. In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia. Behav Brain Res 2009; 204: 1–31.

Kägi

Bhatia

Tolosa

. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010; 81: 5–12.

Bajaj

Hauser

Grachev

. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2013; 84: 1288–1295.

Marsden

. Brain pigment and its relation to brain catecholamines. Lancet 1965; 2: 475–476.

Graham

. On the origin and significance of neuromelanin. Arch Pathol Lab Med 1979; 103: 359–362.

Bazelon

Fenichel

Randall

. Studies on neuromelanin. I A melanin system in the human adult brainstem. Neurology 1967; 17: 512–519.

Sasaki

Shibata

Tohyama

, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006; 31;17: 1215–1218.

Miyoshi

Ogawa

Kitao

, et al. Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and ¹²³I-metaiodobenzylguanidine scintigraphy. AJNR Am J Neuroradiol 2013; 34: 2113–2118.

10.

Schwarz

Rittman

Gontu

, et al. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord 2011; 26: 1633–1638.

11.

Kashihara

Shinya

Higaki

. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosci 2011; 18: 1093–1096.

12.

Isaias

Trujillo

Summers

, et al. Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease. Front Aging Neurosci 2016; 8: 196.

13.

Kuya

Shinohara

Miyoshi

, et al. Correlation between neuromelanin-sensitive MR imaging and ¹²³I-FP-CIT SPECT in patients with parkinsonism. Neuroradiology 2016; 58: 351–356.

14.

Kuya

Ogawa

Shinohara

, et al. Evaluation of Parkinson's disease by neuromelanin-sensitive magnetic resonance imaging and 123I-FP-CIT SPECT. Acta Radiol 2018; 59: 593–598.

15.

Hoehn

Yahr

. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442.

16.

Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670–676.

17.

Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9.

18.

Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80:496–503.

19.

Tossici-Bolt L, Hoffmann SM, Kemp PM, et al. Quantification of 123I-FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging 2006;33:1491–1499.

20.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452–458.

21.

Brigo F, Matinella A, Erro R, et al. ¹²³I-FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur J Neurol 2014;21:1369–1390.

22.

Rossi C, Frosini D, Volterrani D, et al. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. Eur J Neurol 2010;17:626–630.

23.

Contrafatto D, Mostile G, Nicoletti A, et al. 123I-FP-CIT-SPECT asymmetry index to differentiate Parkinson's disease from vascular parkinsonism. Acta Neurol Scand 2012;126:12–16.

24.

Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003;18 Suppl 7:S28–33.

25.

Tinazzi M, Antonini A, Bovi T, et al. Clinical and 123I-FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 2009;256:910–915.

26.

Benítez-Rivero S, Lama MJ, Huertas-Fernández I, et al. Clinical features and neuropsychological profile in vascular parkinsonism. J Neurol Sci 2014 15;345:193–197.

27.

Kitao

Matsusue

Fujii

, et al. Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies. Neuroradiology 2013; 55: 947–953.

28.

Kashihara

Shinya

Higaki

. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Intern Med 2011; 50: 1683–1687.

29.

Matsuura

Maeda

Yata

, et al. Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy. Eur Neurol 2013; 70: 70–77.

30.

Ohtsuka

Sasaki

Konno

, et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 2014; 20: 755–760.

31.

Südmeyer

Antke

Zizek

, et al. Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach. J Nucl Med 2011; 52: 733–740.

32.

Stoffers

Booij

Bosscher

, et al. Early-stage [123I] beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. Eur J Nucl Med Mol Imaging 2005; 32: 689–695.

33.

Brücke

Asenbaum

Pirker

, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997; 50: 9–24.